Alterations of the Female Reproductive System in Islet Recipient Receiving Immunosuppression

Cell Transplantation

Brief Communication

Andrea Corrales¹  Shari Messinger¹  Camillo Ricordi²  Maria Isabel Del Olmo Garcia³  Rodolfo Alejandro⁴  Vincenzo Lauriola⁵  Altagracia Gomez Aracena⁶ 

[1] Diabetes Research Institute, Miami, FL, University of Miami Miller School of Medicine, USA;Diabetes Research Institute, Miami, FL, University of Miami Miller School of Medicine, USA;DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA;Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA;Jackson Memorial Hospital-University of Miami Transplant Institute, University of Miami Miller School of Medicine, Miami, FL, USA;Diabetes Research Institute, Miami, FL, University of Miami Miller School of Medicine, USA;Department of Endocrinology and Nutrition, University Hospital La Fe, Valencia, Spain;Diabetes Research Institute, Miami, FL, University of Miami Miller School of Medicine, USA;Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA;Diabetes Research Institute, Miami, FL, University of Miami Miller School of Medicine, USA;Facoltá di Scienze Motorie, Universitá degli Studi di Milano, Milano, Italy;Diabetes Research Institute, Miami, FL, University of Miami Miller School of Medicine, USA;Instituto Tecnologico de Santo Domingo (INTEC), Santo Domingo, Dominican Republic;

关键词: Type 1 diabetes;    Islet transplantation;    Immunosuppression;    Sirolimus;    Reproductive system;   

DOI  :  10.3727/096368910X557209

 received in 2010-10-22, accepted in 2010-12-13,  发布年份 2011

来源: Sage Journals

【 摘 要 】

Pancreatic islet allotransplantation is an option for patients with unstable type 1 diabetes mellitus (T1DM). Major improvements in islet isolation techniques and the implementation of steroid-free immunosuppressive regimens can maintain insulin independence in the majority of T1DM for at least 1 year after transplantation. Recent studies have emphasized the impact of sirolimus on female reproductive tract. In this communication we report on the alterations of the female reproductive tract in 18 chronically immunosuppressed patients with T1DM following allogenic islet transplantation. Previous research has shown development of ovarian cysts in islet transplant patients receiving sirolimus. We extensively reevaluated this and other possible side effects on the female reproductive system. These side effects have been underestimated, although they are significant, requiring surgical or intensive medical treatment. Pre- and posttransplant gynecological evaluation should be performed to address the development of complications secondary to sirolimus in order to intervene sooner with alternative therapies.

【 授权许可】

Unknown   
© 2011 Cognizant Comm. Corp.